Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2010

01-08-2010 | Original Article

Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D)

Authors: Reiko Tajima, Masahide Kondo, Hirayasu Kai, Chie Saito, Masafumi Okada, Hideto Takahashi, Mariko Doi, Shuichi Tsuruoka, Kunihiro Yamagata

Published in: Clinical and Experimental Nephrology | Issue 4/2010

Login to get access

Abstract

Background

Chronic kidney disease (CKD) is a health-related quality-of-life (HRQOL) deteriorating disease which is not only a public health but also a socioeconomic problem. Interest in developing cost-effective interventions to control CKD has increased. The aim of this study was to measure HRQOL in terms of quality-adjustment weights for cost-effectiveness analysis using EQ-5D in patients with CKD. The relationships between the measured HRQOL and clinical indices/complications were also analyzed.

Methods

EQ-5D, a generic preference-based instrument, was administered to 569 CKD outpatients at Tsukuba University Hospital between November and December 2008. The response rate was 94.4% (537/569). Data on sex, age, creatinine, hemoglobin, serum albumin and eGFR were obtained from the patients’ records. Data on the presence of complications such as hypertension, diabetes, and history of cardiovascular disease (CVD) were also retrieved.

Results

Measured quality-adjustment weights by the CKD stage were 0.940 (95% CI 0.915–0.965), 0.918 (0.896–0.940), 0.883 (0.857–0.909), 0.839 (0.794–0.884), and 0.798 (0.757–0.839) for stages 1–5, respectively. The decrease in weight was significant by ANOVA (P < 0.0001), and the weight for all stages was 0.885 (0.871–0.898). There was a positive relationship between hemoglobin/serum albumin and the weight. The presence of hypertension lowered the weight from 0.910 (0.885–0.936) to 0.874 (0.858–0.891), diabetes from 0.901 (0.886–0.917) to 0.840 (0.811–0.869), and CVD from 0.892 (0.878–0.906) to 0.783 (0.718–0.848).

Conclusions

HRQOL decreases with progression of CKD stage and/or presence of anemia, undernutrition, hypertension, diabetes, or history of CVD.
Literature
1.
go back to reference K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Evaluation, classification, and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis. 2002;39:76–110.CrossRef K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Evaluation, classification, and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis. 2002;39:76–110.CrossRef
2.
go back to reference Levey AS, Eckardt KW, Tsukamoto Y, Levin A, Coresh J. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRefPubMed Levey AS, Eckardt KW, Tsukamoto Y, Levin A, Coresh J. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRefPubMed
3.
go back to reference Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease CKD in Japanese general population. Clin Exp Nephrol. 2009;13:621–30.CrossRefPubMed Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease CKD in Japanese general population. Clin Exp Nephrol. 2009;13:621–30.CrossRefPubMed
4.
go back to reference Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec 31, 2008. Tokyo: Japanese Society for Dialysis Treatment; 2009 (in Japanese). Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec 31, 2008. Tokyo: Japanese Society for Dialysis Treatment; 2009 (in Japanese).
5.
go back to reference Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629–36.PubMed Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629–36.PubMed
6.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed
7.
go back to reference Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–10.PubMed Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–10.PubMed
8.
go back to reference Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med. 2005;165:2659–65.CrossRefPubMed Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med. 2005;165:2659–65.CrossRefPubMed
9.
go back to reference Gold RM, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. Gold RM, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
10.
go back to reference Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
11.
go back to reference Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, Burrows-Hudson S, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD Study. Am J Kidney Dis. 2005;45:658–66.CrossRefPubMed Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, Burrows-Hudson S, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD Study. Am J Kidney Dis. 2005;45:658–66.CrossRefPubMed
12.
go back to reference Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life in CKD patients receiving treatment for anemia. Kidney Int. 2009;75:15–24.CrossRefPubMed Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life in CKD patients receiving treatment for anemia. Kidney Int. 2009;75:15–24.CrossRefPubMed
13.
go back to reference Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press; 2007. Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press; 2007.
14.
go back to reference Japanese EuroQol Translation Team. The development of the Japanese EuroQol instrument. J Health Care Soc. 1997;8:109–23. (in Japanese). Japanese EuroQol Translation Team. The development of the Japanese EuroQol instrument. J Health Care Soc. 1997;8:109–23. (in Japanese).
15.
go back to reference Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11:341–53.CrossRefPubMed Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11:341–53.CrossRefPubMed
16.
go back to reference Matsuo S, Imai E, Horino M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horino M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
17.
go back to reference Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829–36.CrossRef Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829–36.CrossRef
18.
go back to reference Gorodetskaya I, Zenion S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801–8.CrossRefPubMed Gorodetskaya I, Zenion S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801–8.CrossRefPubMed
19.
go back to reference Furlong WJ, Feeny DH, Torrance GW, Barr RD. The health utilities index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med. 2001;33:375–84.CrossRefPubMed Furlong WJ, Feeny DH, Torrance GW, Barr RD. The health utilities index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med. 2001;33:375–84.CrossRefPubMed
20.
go back to reference Dale PL, Hutton J, Elgazzar H. Utility of health states in chronic kidney disease: a structured review of the literature. Curr Med Res Opin. 2008;24:193–206.CrossRefPubMed Dale PL, Hutton J, Elgazzar H. Utility of health states in chronic kidney disease: a structured review of the literature. Curr Med Res Opin. 2008;24:193–206.CrossRefPubMed
21.
go back to reference de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy. 1998;44:215–32.CrossRefPubMed de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy. 1998;44:215–32.CrossRefPubMed
22.
go back to reference Greiner W, Obermann K, Schulenburg JM. Socio-economic evaluation of kidney transplantation in Germany. Arch Hell Med. 2001;18:147–55. Greiner W, Obermann K, Schulenburg JM. Socio-economic evaluation of kidney transplantation in Germany. Arch Hell Med. 2001;18:147–55.
23.
go back to reference Manns B, Johnson JA, Taub K, Mortis G, Donaldson GC. Quality of life in patients treated with haemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol. 2003;60:341–51.PubMed Manns B, Johnson JA, Taub K, Mortis G, Donaldson GC. Quality of life in patients treated with haemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol. 2003;60:341–51.PubMed
24.
go back to reference Sennfält K, Magnusson M, Carlsson P. Comparison of haemodialysis and peritoneal dialysis—a cost-utility analysis. Perit Dial Int. 2002;22:39–47.PubMed Sennfält K, Magnusson M, Carlsson P. Comparison of haemodialysis and peritoneal dialysis—a cost-utility analysis. Perit Dial Int. 2002;22:39–47.PubMed
25.
go back to reference Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin. 2006;22:1929–37.CrossRefPubMed Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin. 2006;22:1929–37.CrossRefPubMed
26.
go back to reference Japanese Society of Nephrology. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Tokyo: Igakusha; 2007 (in Japanese). Japanese Society of Nephrology. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Tokyo: Igakusha; 2007 (in Japanese).
27.
go back to reference Sakamaki H, Ikeda S, Ikegami N, Uchigata Y, Iwamoto Y, Origasa H, et al. Measurement of HRQL using EQ-5D in patients with Type 2 diabetes mellitus in Japan. Value Health. 2006;9:47–53.CrossRefPubMed Sakamaki H, Ikeda S, Ikegami N, Uchigata Y, Iwamoto Y, Origasa H, et al. Measurement of HRQL using EQ-5D in patients with Type 2 diabetes mellitus in Japan. Value Health. 2006;9:47–53.CrossRefPubMed
Metadata
Title
Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D)
Authors
Reiko Tajima
Masahide Kondo
Hirayasu Kai
Chie Saito
Masafumi Okada
Hideto Takahashi
Mariko Doi
Shuichi Tsuruoka
Kunihiro Yamagata
Publication date
01-08-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0304-1

Other articles of this Issue 4/2010

Clinical and Experimental Nephrology 4/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.